MedBridgeNZWhen standard cancer treatments become limited, biomarker-driven oncology trials in China may offer new pathways for global patients. As a medical concierge provider, we handle the complex medical translation and site shortlisting.
Read the guide: https://zurl.co/u9k2s
#MedicalTourismChina #ClinicalTrials #Oncology #MedicalConcierge
access biomarker-driven oncology trials in China
Home > Blog > Advanced Therapies & TechnologyKey Takeaways • China's oncology trial landscape focuses heavily on biomarker-driven protocols, including ADCs, bispecific antibodies, and CAR-T therapies. • Access requires verified molecular evidence before trial-site shortlisting or outreach begins, rather than broad open enrollment. • Administrative barriers include language, residency rules, and complex hospital intake systems, necessitating professional coordination. • Official optimizatio